On 7 – 9 September 2022, ECDC organised with the Ministry of Health and the Georgian National Center for Disease Control and Public Health a consultative meeting with Georgian public health representatives and stakeholders.
The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) have issued a joint statement (link) providing updated public health considerations on the use of the newly authorised adapted COVID-19 vaccines to support the planning of the autumn and winter vaccination campaigns.
In order to maintain safe school environments and minimise student and staff absences, it is important to continue ensuring the prevention of the transmission of respiratory viruses such as influenza, respiratory syncytial virus (RSV), norovirus and SARS-CoV-2.
This protocol outlines the methods for a prospective cohort study in long-term care facilities (LTCFs) to evaluate the effectiveness of COVID-19 vaccines in preventing laboratory-confirmed SARS-CoV-2 symptomatic infection in LTCF residents.
This document offers an overview of the available scientific and epidemiological evidence and provides public health considerations to support decisions on the implementation of additional booster doses of COVID-19 vaccine.
The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) have updated public health recommendations on the use of additional booster doses of COVID-19 vaccines this summer and in the upcoming autumn and winter seasons.